Market closedLast updated 29 July 2026, 9:38 pm ISTData NSENot investment advice
Biofil Chemicals & Pharmaceuticals

Biofil Chemicals & Pharmaceuticals Share Price Today (BIOFILCHEM)

NSE: BIOFILCHEMBSE 524396HealthcarePharmaceuticalswww.biofilgroup.net
TechnicalsTV Chart
32.64
0.18−0.55%
Overall Score55/100
Day range32
₹32.64
33
52-week26
₹32.64
46
Above low+27.5%
Below high29.6%
Range position34%
Open32.82
Prev Close32.82
Bid32.62100
Ask32.67100

TODAY IN ONE LINE

BIOFILCHEM slipped 0.6% on light volume, in line with Nifty's -0.0% move.

With a market cap of ₹52.73 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.

Volume4.0K47%vs 20D avg
Market Cap₹52.73 Cr.
Promoter46.79%
Face Value₹10
Fwd P/E
PEG0.28
EV/EBITDA15.37
P/S1.7
ROA4.61%
Beta1.13
Div Payout
THE STOCK SCORE

How good is this company?

Overall performance across 5 key dimensions.

Overall Score55/100
Updated 28 Jul
Each card tappable → shows formula + inputs
FLAGS & NEWS

Biofil Chemicals & Pharmaceuticals flags & news 

Key strengths, potential risks, and recent updates.

4 green flags🚩 2 red flags

Green Flags

  • Earnings GrowthEPS (TTM) grew by a solid 10.8% YoY
  • High Capital EfficiencyROCE of 15.8% indicating pricing power
  • Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
  • Zero Pledge RiskNo recent active promoter pledging found

Red Flags

  • Sales ContractionQuarterly sales dropped 9.3% YoY
  • Rising Receivables vs SalesReceivables grew 16.0% outpacing sales growth of -16.6%

Latest Biofil Chemicals & Pharmaceuticals News

THE CHANGELOG

What changed recently?

Recent events, corporate actions, and announcements.

No recent changes found for this period.
🔒Prime: full history + alerts on this stock
Valuation

Biofil Chemicals & Pharmaceuticals Limited valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for Biofil Chemicals & Pharmaceuticals Limited, framed against the sector median so the premium or discount is obvious at a glance.

Key MetricsMarket + reported · 28 Jul 2026Consolidated

Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.

Valuation

Valuation

Market Cap
₹52.73 Cr.
P/E Ratio
P/B Ratio
EPS
₹1.71
Profitability

Profitability

ROE
13.8%
ROCE
15.8%
Net Margin
9.81%
Op Margin
2.29%
Growth

Growth

EPS YoY
10.8%
Revenue YoY
-9.3%
Qtr Sales
-9.34%
Qtr Profit
5%
Financial Health

Financial Health

Debt / Equity
0.14
Book Value
₹13.21
Div Yield
Promoter Holding
46.79%
Technicals

Biofil Chemicals & Pharmaceuticals Limited technical analysis: indicators, pivots and CPR.

Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Biofil Chemicals & Pharmaceuticals Limited — derived from the live tape, not yesterday's close.

Biofil Chemicals & Pharmaceuticals Limited last traded at ₹32.64 with an intraday range of ₹32.16–₹33.18 — live indicator, pivot and CPR signals below.

Last updated: 29 July 2026, 9:38 pm IST

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Live: ₹32.64
LevelPrice (₹)Distance% Δ
R435.20+2.56+7.84%
R334.18+1.54+4.72%
R233.68+1.04+3.19%
R133.16+0.52+1.59%
PIVOT32.660.020.06%
CURRENT32.64
S132.14-0.50-1.53%
S231.64-1.00-3.06%
S331.12-1.52-4.66%
S430.10-2.54-7.78%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 32.65P: 32.66TC: 32.67
R1
R2
R3
R4
indicator
LTP: 32.64
PDH: 33.45
PDL: 32.11
● Market Sentiment

BIOFILCHEM is trading Below CPR, indicating Bearishness

● CPR Width

CPR is Narrower, suggesting likely for trending moves

● Opening Range

Day's range: 32.8232.82

● Price Position

Trading Inside opening range

Financials

Biofil Chemicals & Pharmaceuticals Limited financials: P&L, balance sheet, cash flow, ratios.

Reported annual and quarterly results for Biofil Chemicals & Pharmaceuticals Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.

Biofil Chemicals & Pharmaceuticals Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹52.73 Cr. and reported EPS of ₹1.71.

iTap any row for a plain-English meaningChange vs a year ago — green means the move is healthy for that line, red means it isn’tDerivedCalculated by us, not reported directly
all values in ₹ Cr unless marked % / x / ₹ · fiscal-period end shown · reported figures via Stockezee financials API · annual results may be audited; quarterly results may be unaudited or limited-review
Segment Analysis

Biofil Chemicals & Pharmaceuticals segment analysis : revenue and profit mix.

Disclosed business segments at Biofil Chemicals & Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.

Biofil Chemicals & Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Thesis

The Bull, Bear, and Flip case for Biofil Chemicals & Pharmaceuticals Limited.

Our AI distills the core fundamental drivers supporting Biofil Chemicals & Pharmaceuticals Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.

Biofil Chemicals & Pharmaceuticals Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.

bull case

What you're getting.

  • Near-zero debt-to-equity ratio of 0.0014x provides exceptional financial flexibility.

  • Latest quarterly EPS grew 6.3% YoY despite revenue headwinds.

  • TTM EPS grew 10.8% YoY, signaling positive earnings momentum.

  • P/E of 20.29x trades below peer median, offering valuation comfort.

  • Diversified pharma-chemicals business with vertical integration in packaging.

bear case

Key Risks.

  • TTM revenue declined 9.3% YoY, reflecting persistent demand weakness.

  • Operating margin of 1.33% remains critically thin versus peer average.

  • Operating cash flow negative ₹0.60 Cr (FY26); chronic cash burn despite profits.

  • Trade receivables ₹27.59 Cr represent 97% of revenue; severe collection risk.

  • Zero institutional ownership and negligible FII/DII holdings signal low confidence.

flip conditions

Flip Conditions.

  • Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.

  • Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.

  • Return-quality risk. ROE below 9% would indicate weaker capital compounding.

Shareholding

Biofil Chemicals & Pharmaceuticals shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in Biofil Chemicals & Pharmaceuticals — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

AnnualJun 2026

Promoters46.79%
DII0.08%
Public53.13%

Ownership Distribution

Promoters
46.79%
Domestic Institutions
0.08%
Retail & Public
53.13%

Category Trends

Foreign Institutions Breakdown
Total Holding: 0.00%
Net Change: +0.00%
Category Total0.00%
Total Holding0.00%
Net Change+0.00%
Aggregate Data
Institution Name
Trend (Last 6)
Holding %
QoQ Change
YoY ChangePeriod

No detailed foreign institutions data disclosed

Detailed institutional breakdown is not disclosed by the company for foreign institutions

Peers

Biofil Chemicals & Pharmaceuticals Limited peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Biofil Chemicals & Pharmaceuticals Limited is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
₹4.76 Lakh Cr
Best Profit Growth
Sun Pharma Advanced Research Company Limited
3047.00 %
Highest Dividend Yield
Sanofi India Limited
7.15 %

Peer Comparison

Company Name
09 · Chart Patterns

Biofil Chemicals & Pharmaceuticals Limited chart patterns: breakouts, tops and bottoms.

Auto-detected classical chart patterns for Biofil Chemicals & Pharmaceuticals Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.

  1. 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
  2. 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
  3. 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
  4. 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
  5. 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Detection
History
Click a pattern card to draw the pattern shape on the candles — labeled pivots (Head, Shoulders, Bottoms), neckline, breakout point, projection and invalidation. Click again to clear.
0 patterns
Historical accuracy
0 of 0 confirmed patterns reached projection
Avg move when projection reached
measured from break level
Avg sessions to projection
after confirmation
Best pattern on BIOFILCHEM
needs ≥3 completions

Pattern history — every completed pattern and its outcome

No completed patterns yet.
View full BIOFILCHEM pattern history & scanner →
Delivery Conviction

Biofil Chemicals & Pharmaceuticals Limited delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for Biofil Chemicals & Pharmaceuticals Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in Biofil Chemicals & Pharmaceuticals Limited stood at 80.3% of traded volume, against a 20-day average of 67.7%.

Avg Delivery (20D)67.7%+12.6 ppt latest vs avg
Highest Delivery90.7%on 17 Jul
Avg Volume (20D)7.7 K20-day run-rate
Conviction Trend↑ Strengthening+12.6 ppt latest read
Volume & Delivery · last 20 sessions
Exchange Filings & Investor Updates

Biofil Chemicals & Pharmaceuticals announcements: results, concalls, ratings, M&A.

Filings Biofil Chemicals & Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

Biofil Chemicals & Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 46 documents below.

  1. 01 Jul 2026Certificate under SEBI (Depositories and Participants) Regulations, 2018View PDF

    Certificate under SEBI (Depositories and Participants) Regulations, 2018

    Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  2. 01 Jun 2026Copy of Newspaper PublicationView PDF

    Copy of Newspaper Publication

    Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication pursuant to Regulation 47 of SEBI (Listing…

  3. 07 May 2026Disclosure under SEBI Takeover RegulationsView PDF

    Disclosure under SEBI Takeover Regulations

    KETAN SHAH has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial…

  4. 05 May 2026UpdatesView PDF

    Updates

    Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Intimation under Regulation 30 of the SEBI (Listing Obligations and…

  5. 03 Apr 2026Copy of Newspaper PublicationView PDF

    Copy of Newspaper Publication

    Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Submission of Publication in Newspaper pursuant to SEBI circular for…

Corporate Actions

Biofil Chemicals & Pharmaceuticals dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue Biofil Chemicals & Pharmaceuticals has declared, sequenced by announce and record date.

Biofil Chemicals & Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

Insider Activity

Biofil Chemicals & Pharmaceuticals insider trading: promoter and management activity.

Promoter, director and designated-employee transactions in Biofil Chemicals & Pharmaceuticals as reported to SEBI — buying and selling signals from the people who know the business best.

Biofil Chemicals & Pharmaceuticals insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).

InsiderCategoryTxn DateActionQuantityValue (₹)Price
NIYATI SHAHInsider18 Mar 2026buy+32.7 K
MEENA SHAHInsider18 Mar 2026buy+32.7 K
NIYATI SHAHInsider18 Mar 2026buy+32.7 K
MEENA SHAHInsider18 Mar 2026buy+32.7 K
MEENA SHAHInsider18 Mar 2026buy+32.7 K
NIYATI SHAHInsider18 Mar 2026buy+32.7 K
MEENA SHAHInsider18 Mar 2026buy+32.7 K
NIYATI SHAHInsider18 Mar 2026buy+32.7 K
Niyati ShahInsider06 Jun 2025buy+4.94 L
About the Company

About Biofil Chemicals & Pharmaceuticals Limited: business, sector, key facts.

What Biofil Chemicals & Pharmaceuticals Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

Biofil Chemicals & Pharmaceuticals Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: BIOFILCHEM, BSE: 524396.

BIOFILCHEM
Healthcare

Biofil Chemicals & Pharmaceuticals Limited

NSE · BIOFILCHEM·BSE · 524396·www.biofilgroup.net

Biofil Chemicals and Pharmaceuticals Limited (Biofilchem) is an Indian company primarily engaged in the manufacturing and trading of pharmaceuticals and chemicals. Their business model encompasses two key divisions: Pharmaceuticals and Chemicals. This dual approach allows them to cater to a broader market, encompassing both the production of essential drug components and the finished pharmaceutical products themselves.

The Chemical division focuses on the production and supply of a range of basic drugs and chemical compounds. Their product portfolio includes a variety of inorganic salts crucial in pharmaceutical formulations, such as sodium chloride, potassium chloride, and sodium citrate. They also manufacture organic compounds like diethylcarbamazine citrate, used in anthelmintic medications. In addition to these, Biofilchem produces key excipients, including ferrous sulphate (in both dried and standard forms) and ferrous fumarate, which are frequently used in the manufacture of iron supplements. The company also supplies microcrystalline cellulose, a common pharmaceutical excipient for tablet formulation, and dicyclomine hydrochloride, an antispasmodic agent.

Beyond the core chemical production, Biofilchem also contributes to the packaging side of the pharmaceutical industry. They manufacture plastic drippers and caps, essential components for packaging liquid medications, providing a comprehensive supply chain solution for pharmaceutical companies. This vertical integration strategy strengthens their position within the market and potentially offers improved cost control.

Furthermore, Biofilchem offers job work services, acting as a contract manufacturer for other pharmaceutical companies. This facet of their business involves producing pharmaceutical drugs on behalf of third parties, leveraging their existing manufacturing capabilities to expand their revenue streams and diversify their client base. This service likely contributes to their overall profitability and ensures consistent utilization of their production facilities.

In summary, Biofilchem's business is multifaceted, ranging from the production of essential chemical raw materials and excipients to the manufacturing of finished pharmaceutical products and packaging components. The company's integrated approach, encompassing manufacturing, trading, and contract manufacturing, allows for a diversified and relatively resilient business model within the Indian pharmaceutical market. Established in 1985 and headquartered in Indore, India, Biofilchem has developed a strong foundation within the pharmaceutical and chemical landscape.

company facts
Employees
SectorHealthcare
HeadquartersIndore, India
Market Cap₹52.73 Cr.
Listed OnNSE
leadership11 on record
Joseph Chacko
Head of Administration
Mr. Apoorv Jain
Company Secretary & Compliance Officer
Mr. Ashok Ramawat
Non-Executive Independent Director
Mr. Ketan Shah
MD & Chairman
Mr. Meet Shah
Additional Promoter Non-Executive Director
Mr. Pavan Rajput
Chief Financial Officer
Mr. Pavan Singh Rajput
Chief Financial Officer
Mr. Satish Beohar
Additional Non-Executive Independent Director
Shri. Ketan Shah
Whole Time Director
Smt. Gayatri Padiyar
Non-Executive Independent Director
Vinayak Bhopte
Chief Chemist
§ ∞ · Plainly Answered

Questions investors ask about Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?

The current share price of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) is ₹32.64. Today, the stock has declined by ₹0.18 (0.55%), trading in a range of ₹32.16 to ₹33.18. The stock opened at ₹32.82 with a trading volume of 4,048 shares.

02What is the 52-week high and low price of Biofil Chemicals & Pharmaceuticals Limited stock?

The 52-week high price of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) is ₹46.34, while the 52-week low is ₹25.6. Currently trading at ₹32.64, the stock is 33.9% away from its 52-week low and 29.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

03What is the dividend yield of Biofil Chemicals & Pharmaceuticals Limited and when is the next dividend?

Biofil Chemicals & Pharmaceuticals Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹32.64, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

04How is Biofil Chemicals & Pharmaceuticals Limited stock performing today in the market?

Biofil Chemicals & Pharmaceuticals Limited stock opened at ₹32.82 and is currently trading at ₹32.64, showing a decline of ₹0.18 (0.55%). The intraday high is ₹33.18 and low is ₹32.16. The trading volume stands at 4,048 shares, indicating moderate market participation today.

05What is the market capitalization of Biofil Chemicals & Pharmaceuticals Limited?

Biofil Chemicals & Pharmaceuticals Limited has a market capitalization of ₹52.73 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹32.64) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.

06What is the ROE and ROCE of Biofil Chemicals & Pharmaceuticals Limited?

Biofil Chemicals & Pharmaceuticals Limited has a Return on Equity (ROE) of 13.80% and Return on Capital Employed (ROCE) of 15.80%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These are moderate returns, suggesting decent operational efficiency. Higher percentages generally indicate better financial performance.

07Which sector and industry does Biofil Chemicals & Pharmaceuticals Limited belong to?

Biofil Chemicals & Pharmaceuticals Limited operates in the Healthcare sector and belongs to the Pharmaceuticals industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.

08What is the debt-to-equity ratio of Biofil Chemicals & Pharmaceuticals Limited?

Biofil Chemicals & Pharmaceuticals Limited has a debt-to-equity ratio of 0.14, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.

Disclaimer

The data, ratios and commentary about Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.